Tempus Completes Acquisition of Ambry Genetics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
TD Cowen Reinstates Tempus AI Inc (TEM) at Buy
February 5, 2025 7:00 AM ESTTD Cowen analyst Dan Brennan reinstates coverage on Tempus AI Inc (NASDAQ: TEM) with a Buy rating and a price target of $74.00.
The analyst comments "TEM closed its Ambry acquisition & we reinstate coverage with Buy. The deal affords TEM w/ a $300M+, profitable... More
